KR100507616B1 - 페린도프릴 또는 이의 약제학적으로 허용되는 염의 합성 방법 - Google Patents
페린도프릴 또는 이의 약제학적으로 허용되는 염의 합성 방법 Download PDFInfo
- Publication number
- KR100507616B1 KR100507616B1 KR10-2002-7013376A KR20027013376A KR100507616B1 KR 100507616 B1 KR100507616 B1 KR 100507616B1 KR 20027013376 A KR20027013376 A KR 20027013376A KR 100507616 B1 KR100507616 B1 KR 100507616B1
- Authority
- KR
- South Korea
- Prior art keywords
- formula
- compound
- perindopril
- per mole
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims abstract description 16
- 150000003839 salts Chemical class 0.000 title claims abstract description 7
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 title claims description 20
- 229960002582 perindopril Drugs 0.000 title claims description 19
- 230000015572 biosynthetic process Effects 0.000 title abstract description 3
- 238000003786 synthesis reaction Methods 0.000 title abstract description 3
- 230000008569 process Effects 0.000 claims abstract description 7
- 150000001875 compounds Chemical class 0.000 claims description 23
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 21
- 238000005859 coupling reaction Methods 0.000 claims description 8
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 claims description 5
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 claims description 4
- 238000009903 catalytic hydrogenation reaction Methods 0.000 claims description 4
- -1 benzyl ester Chemical class 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 230000002194 synthesizing effect Effects 0.000 claims description 3
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical class CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 claims description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 238000010511 deprotection reaction Methods 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- VIJMMQUAJQEELS-UHFFFAOYSA-N n,n-bis(ethenyl)ethenamine Chemical compound C=CN(C=C)C=C VIJMMQUAJQEELS-UHFFFAOYSA-N 0.000 claims description 2
- 125000004494 ethyl ester group Chemical group 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- 239000012535 impurity Substances 0.000 description 10
- UAEPNZWRGJTJPN-UHFFFAOYSA-N methylcyclohexane Chemical compound CC1CCCCC1 UAEPNZWRGJTJPN-UHFFFAOYSA-N 0.000 description 6
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- GYNNXHKOJHMOHS-UHFFFAOYSA-N methyl-cycloheptane Natural products CC1CCCCCC1 GYNNXHKOJHMOHS-UHFFFAOYSA-N 0.000 description 3
- 238000001308 synthesis method Methods 0.000 description 3
- 102400000344 Angiotensin-1 Human genes 0.000 description 2
- 101800000734 Angiotensin-1 Proteins 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 2
- ARGCRCXTJMQKNA-KKUMJFAQSA-N benzyl (2s,3as,7as)-2,3,3a,4,5,6,7,7a-octahydro-1h-indole-2-carboxylate Chemical compound O=C([C@H]1N[C@H]2CCCC[C@H]2C1)OCC1=CC=CC=C1 ARGCRCXTJMQKNA-KKUMJFAQSA-N 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- AUVAVXHAOCLQBF-YUMQZZPRSA-N (2s)-2-[[(2s)-1-ethoxy-1-oxopentan-2-yl]azaniumyl]propanoate Chemical compound OC(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC AUVAVXHAOCLQBF-YUMQZZPRSA-N 0.000 description 1
- NRAMCLOSUDJHAH-YUMQZZPRSA-N (2s)-2-[[(2s)-1-ethoxy-1-oxopropan-2-yl]amino]pentanoic acid Chemical compound CCC[C@@H](C(O)=O)N[C@@H](C)C(=O)OCC NRAMCLOSUDJHAH-YUMQZZPRSA-N 0.000 description 1
- 102400000345 Angiotensin-2 Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000037849 arterial hypertension Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- ZNAYHAPFFQRGES-SVXFZJLFSA-N benzyl (2s,3as,7as)-1-[(2s)-2-[[(2s)-1-ethoxy-1-oxopentan-2-yl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylate Chemical compound O=C([C@@H]1C[C@@H]2CCCC[C@@H]2N1C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)OCC1=CC=CC=C1 ZNAYHAPFFQRGES-SVXFZJLFSA-N 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000006264 debenzylation reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- UYMKPFRHYYNDTL-UHFFFAOYSA-N ethenamine Chemical compound NC=C UYMKPFRHYYNDTL-UHFFFAOYSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- IYNMDWMQHSMDDE-MHXJNQAMSA-N perindopril erbumine Chemical compound CC(C)(C)N.C1CCC[C@@H]2N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H](C(O)=O)C[C@@H]21 IYNMDWMQHSMDDE-MHXJNQAMSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Indole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (7)
- 페린도프릴 또는 이의 약제학적으로 허용되는 염을 산업적 규모로 합성하기 위한 방법으로서, 하기 화학식(IV)의 벤질 에스테르를, 에틸 에스테르 중에서 사용되는 화학식(IV)의 화합물 몰당 1-하이드록시벤조트리아졸 0.4 내지 0.6몰량의 존재하에, 그리고 사용되는 화학식(IV)의 화합물의 몰당 다이시클로헥실카르보다이이미드 1 내지 1.2몰량의 존재하에, 트리에틸아민의 부재하에 또는 사용되는 화학식(IV)의 화합물 몰당 트리에틸렌아민 1몰량 이하의 존재하에, 20 내지 77℃의 온도에서 하기 화학식(V)의 화합물과 커플링 반응시켜 분리시킨 후 하기 화학식(VI)의 화합물의 수득하고, 이것의 헤테로사이클의 카르복실기를 촉매적 수소화에 의해 탈보호시켜 하기 화학식(I)의 페린도프릴을 수득하거나, 화학식(I)의 페린도프릴을 이의 약제학적으로 허용되는 염으로 전환시킴을 특징으로 하는 방법:상기 식에서,Bn은 벤질기를 나타낸다.
- 제 1 항에 있어서, 페린도프릴을 이의 3차 부틸아민 염 형태로 합성함을 특징으로 하는 방법.
- 제 1 항에 있어서, 커플링 반응이 트리에틸아민의 부재 하에서 수행됨을 특징으로 하는 방법.
- 제 1 항에 있어서, 커플링 반응이 사용되는 화학식(IV)의 화합물의 몰당 트리에틸아민 1몰 또는 이보다 적은 양의 존재 하에서 수행됨을 특징으로 하는 방법.
- 제 4 항에 있어서, 커플링 반응이 사용되는 화학식(IV)의 화합물의 몰당 트리에틸아민 0.25몰 또는 이 보다 적은 양의 존재 하에서 수행됨을 특징으로 하는 방법.
- 삭제
- 삭제
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0004379A FR2807431B1 (fr) | 2000-04-06 | 2000-04-06 | Nouveau procede de synthese du perindopril et de ses sels pharmaceutiquement acceptables |
FR00/04379 | 2000-04-06 | ||
PCT/FR2001/001026 WO2001058868A1 (fr) | 2000-04-06 | 2001-04-05 | Procede de synthese du perindopril et de ses sels pharmaceutiquement acceptables |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20030013381A KR20030013381A (ko) | 2003-02-14 |
KR100507616B1 true KR100507616B1 (ko) | 2005-08-10 |
Family
ID=8848925
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-2002-7013376A Expired - Fee Related KR100507616B1 (ko) | 2000-04-06 | 2001-04-05 | 페린도프릴 또는 이의 약제학적으로 허용되는 염의 합성 방법 |
Country Status (34)
Country | Link |
---|---|
US (1) | US6835843B2 (ko) |
EP (1) | EP1268424B1 (ko) |
JP (1) | JP3939553B2 (ko) |
KR (1) | KR100507616B1 (ko) |
CN (1) | CN1296355C (ko) |
AP (1) | AP1385A (ko) |
AT (1) | ATE369338T1 (ko) |
AU (2) | AU2001248470B2 (ko) |
BG (1) | BG65984B1 (ko) |
BR (1) | BRPI0109836B1 (ko) |
CA (1) | CA2405486C (ko) |
CY (1) | CY1108522T1 (ko) |
CZ (1) | CZ302575B6 (ko) |
DE (1) | DE60129800T2 (ko) |
DK (1) | DK1268424T3 (ko) |
EA (1) | EA005079B1 (ko) |
EE (1) | EE05032B1 (ko) |
ES (1) | ES2291307T3 (ko) |
FR (1) | FR2807431B1 (ko) |
GE (1) | GEP20063797B (ko) |
HR (1) | HRP20020876B1 (ko) |
HU (1) | HU227674B1 (ko) |
ME (1) | ME00441B (ko) |
MX (1) | MXPA02009706A (ko) |
NO (1) | NO324174B1 (ko) |
NZ (1) | NZ521454A (ko) |
OA (1) | OA12242A (ko) |
PL (1) | PL204471B1 (ko) |
PT (1) | PT1268424E (ko) |
RS (1) | RS50808B (ko) |
SK (1) | SK286921B6 (ko) |
UA (1) | UA75070C2 (ko) |
WO (1) | WO2001058868A1 (ko) |
ZA (1) | ZA200207419B (ko) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2827860B1 (fr) * | 2001-07-24 | 2004-12-10 | Servier Lab | Nouveau procede de synthese de derives de l'acide (2s, 3as, 7as)-1-[(s)-alanyl]-octahydro-1h-indole-2-carboxyline et application a la synthese du perindopril |
PT1333026E (pt) * | 2002-01-30 | 2007-09-17 | Servier Lab | ''processo para a preparação de perindopril com elevado grau de pureza e intermediários úteis para a sua síntese'' |
JP2005256847A (ja) * | 2002-02-28 | 2005-09-22 | Nsk Ltd | 車輪用軸受ユニット |
GB2395195A (en) * | 2002-11-18 | 2004-05-19 | Cipla Ltd | Preparation of perindopril from carboxy-protected precursor, & perindopril monohydrates for use as angiotensin converting enzyme (ACE) inhibitors |
AU2003224420B2 (en) | 2003-02-28 | 2009-08-06 | Les Laboratoires Servier | Process for preparation of perindopril and salts thereof |
ES2249691T3 (es) * | 2003-02-28 | 2006-04-01 | Les Laboratoires Servier | Procedimiento de sintesis de derivados del acido (2s,3as,7as)-1-(s)-alanil)-octahidro-1h-indol-2-carboxilico y su utilizacion en la sintesis de perindopril. |
EP1338591B1 (fr) * | 2003-02-28 | 2005-10-26 | Les Laboratoires Servier | Nouveau procédé de synthèse de l'acide (2S, 3aS, 7aS)-perhydroindole-2-carboxylique et de ses esters, et application à la synthèse du perindopril |
ES2250846T3 (es) * | 2003-02-28 | 2006-04-16 | Les Laboratoires Servier | Nuevo procedimiento para la sintesis de perindopril y de sus sales farmaceuticamente aceptables. |
EP1319668B1 (fr) * | 2003-03-12 | 2004-10-27 | Les Laboratoires Servier | Nouveau procédé de synthèse de dérivés de l'acide (2S, 3aS, 7aS)-1-[(S)]-alanyl]-octahydro-1H-indole-2-carboxylique et application à la synthèse du perindopril |
PT1323729E (pt) * | 2003-03-12 | 2005-02-28 | Servier Lab | Novo processo de sintese do acido (2s,3as, 7as)-per-hidroindole-2-carboxilico e os seus esteres e aplicacao a sintese do perindopril |
DE60300581T2 (de) * | 2003-03-12 | 2006-01-19 | Les Laboratoires Servier | Verfahren für die Synthese von Perindopril und seiner pharmazeutisch annehmba- ren Salzen |
WO2004099138A2 (en) * | 2003-05-12 | 2004-11-18 | Cipla Limited | Process for the preparation of perindopril |
EP1636185B1 (de) | 2003-06-24 | 2012-01-11 | Les Laboratoires Servier | Neue kristalline formen von perindopril erbumine |
EP1367062B1 (fr) * | 2003-07-31 | 2006-08-30 | Les Laboratoires Servier | Nouveau procédé de synthèse du perindopril et de ses sels pharmaceutiquement acceptables |
EP1367063B1 (fr) * | 2003-07-31 | 2006-08-23 | Les Laboratoires Servier | Nouveau procédé de synthèse du perindopril et de ses sels pharmaceutiquement acceptables |
ES2336554T3 (es) * | 2003-10-21 | 2010-04-14 | Les Laboratoires Servier | Nuevo metodo para la preparacion de perindopril erbumina cristalina. |
ES2300555T3 (es) * | 2003-12-10 | 2008-06-16 | Les Laboratoires Servier | Procedimiento de sintesis de perindopril y de sus sales farmaceuticamente aceptables. |
US20070172524A1 (en) * | 2004-03-29 | 2007-07-26 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Process for preparing a solid pharmaceutical composition |
GB2413128A (en) * | 2004-04-13 | 2005-10-19 | Neopharma Ltd | Process for the preparation of perindopril |
SI21800A (sl) * | 2004-05-14 | 2005-12-31 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Nov postopek sinteze perindoprila |
ES2255872B1 (es) * | 2004-12-31 | 2007-08-16 | Quimica Sintetica, S.A. | Procedimiento para la preparacion de perindopril erbumina. |
PT1679072E (pt) | 2005-01-06 | 2008-12-22 | Ipca Lab Ltd | Processo para a síntese de derivados de ácido (2s,3as,7as)-1-(s)-alanil-octa-hidro-1h-indole-2-carboxílico e utilização na síntese de perindopril |
US7291745B2 (en) * | 2005-03-21 | 2007-11-06 | Glenmark Pharmaceuticals Limited | Process for the preparation of perindopril |
JP2006290825A (ja) * | 2005-04-13 | 2006-10-26 | Shiono Chemical Co Ltd | アルファ型ペリンドプリルエルブミンの製造法 |
DE102005058166A1 (de) * | 2005-12-05 | 2007-06-06 | Hexal Ag | Matrixkontrolliertes transdermales System mit Amin-Salzen der ACE-Hemmer-Dicarbonsäuren |
WO2007085933A2 (en) * | 2006-01-25 | 2007-08-02 | Glenmark Pharmaceuticals Limited | Process for the preparation of n-[1-(s)-ethoxycarbonyl-1-butyl]-(s)-alanine-dmt complex and its use in the preparation of perindopril |
EP2137148A1 (en) * | 2007-03-22 | 2009-12-30 | Aarti Healthcare Limited | Process for the preparation of perindopril erbumine salt and novel polymorph (s) thereof |
FR2961105B1 (fr) * | 2010-06-15 | 2013-02-08 | Servier Lab | Utilisation de l'association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion de l'angiotensine pour le traitement de l'insuffisance cardiaque |
ES2670854T3 (es) * | 2012-10-10 | 2018-06-01 | Piramal Enterprises Limited | Un proceso mejorado para la preparación de perindoprilo intermedio |
WO2016178591A2 (en) | 2015-05-05 | 2016-11-10 | Gene Predit, Sa | Genetic markers and treatment of male obesity |
PH12018502155B1 (en) | 2016-04-20 | 2024-03-27 | Servier Lab | Pharmaceutical composition comprising a beta blocker, a converting enzyme inhibitor and an antihypertensive or an nsaid |
CN107098949B (zh) * | 2017-04-20 | 2021-03-16 | 上药东英(江苏)药业有限公司 | 一种制备培哚普利叔丁胺盐的绿色合成新工艺 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2503155A2 (fr) * | 1980-10-02 | 1982-10-08 | Science Union & Cie | Nouveaux imino diacides substitues, leurs procedes de preparation et leur emploi comme inhibiteur d'enzyme |
DE3302125A1 (de) * | 1983-01-22 | 1984-07-26 | Boehringer Ingelheim KG, 6507 Ingelheim | Aminosaeure-derivate, verfahren zu ihrer herstellung und verwendung |
FR2620700B1 (fr) * | 1987-09-17 | 1990-06-01 | Adir | Procede de synthese d'alpha amino acides n alkyles et leurs esters. application a la synthese de carboxyalkyl dipeptides |
FR2620709B1 (fr) * | 1987-09-17 | 1990-09-07 | Adir | Procede de synthese industrielle du perindopril et de ses principaux intermediaires de synthese |
-
2000
- 2000-04-06 FR FR0004379A patent/FR2807431B1/fr not_active Expired - Fee Related
-
2001
- 2001-03-20 PL PL346555A patent/PL204471B1/pl unknown
- 2001-03-30 HU HU0101336A patent/HU227674B1/hu not_active IP Right Cessation
- 2001-04-05 AT AT01921486T patent/ATE369338T1/de active
- 2001-04-05 DK DK01921486T patent/DK1268424T3/da active
- 2001-04-05 PT PT01921486T patent/PT1268424E/pt unknown
- 2001-04-05 WO PCT/FR2001/001026 patent/WO2001058868A1/fr active IP Right Grant
- 2001-04-05 CA CA002405486A patent/CA2405486C/fr not_active Expired - Fee Related
- 2001-04-05 AU AU2001248470A patent/AU2001248470B2/en not_active Ceased
- 2001-04-05 MX MXPA02009706A patent/MXPA02009706A/es active IP Right Grant
- 2001-04-05 HR HR20020876A patent/HRP20020876B1/xx not_active IP Right Cessation
- 2001-04-05 JP JP2001558419A patent/JP3939553B2/ja not_active Expired - Fee Related
- 2001-04-05 DE DE60129800T patent/DE60129800T2/de not_active Expired - Lifetime
- 2001-04-05 KR KR10-2002-7013376A patent/KR100507616B1/ko not_active Expired - Fee Related
- 2001-04-05 AU AU4847001A patent/AU4847001A/xx active Pending
- 2001-04-05 CN CNB018073727A patent/CN1296355C/zh not_active Expired - Fee Related
- 2001-04-05 ES ES01921486T patent/ES2291307T3/es not_active Expired - Lifetime
- 2001-04-05 SK SK1418-2002A patent/SK286921B6/sk not_active IP Right Cessation
- 2001-04-05 BR BRPI0109836-5A patent/BRPI0109836B1/pt not_active IP Right Cessation
- 2001-04-05 OA OA1200200306A patent/OA12242A/en unknown
- 2001-04-05 US US10/239,129 patent/US6835843B2/en not_active Expired - Lifetime
- 2001-04-05 AP APAP/P/2002/002630A patent/AP1385A/en active
- 2001-04-05 CZ CZ20023291A patent/CZ302575B6/cs not_active IP Right Cessation
- 2001-04-05 NZ NZ52145401A patent/NZ521454A/en not_active IP Right Cessation
- 2001-04-05 EA EA200201057A patent/EA005079B1/ru not_active IP Right Cessation
- 2001-04-05 EE EEP200200575A patent/EE05032B1/xx not_active IP Right Cessation
- 2001-04-05 RS YUP-738/02A patent/RS50808B/sr unknown
- 2001-04-05 GE GEAP20016679A patent/GEP20063797B/en unknown
- 2001-04-05 EP EP01921486A patent/EP1268424B1/fr not_active Expired - Lifetime
- 2001-04-05 ME MEP-2008-670A patent/ME00441B/me unknown
- 2001-05-04 UA UA2002118786A patent/UA75070C2/uk unknown
-
2002
- 2002-09-16 ZA ZA200207419A patent/ZA200207419B/en unknown
- 2002-10-04 NO NO20024808A patent/NO324174B1/no not_active IP Right Cessation
- 2002-11-04 BG BG107249A patent/BG65984B1/bg unknown
-
2007
- 2007-10-16 CY CY20071101338T patent/CY1108522T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100507616B1 (ko) | 페린도프릴 또는 이의 약제학적으로 허용되는 염의 합성 방법 | |
JP3868957B2 (ja) | (2S,3aS,7aS)−1−[(S)−アラニル]−オクタヒドロ−1H−インドール−2−カルボン酸化合物の新しい合成方法及びペリンドプリルの合成における応用 | |
CN1802384B (zh) | 培哚普利及其可药用盐的新合成方法 | |
KR100825537B1 (ko) | 페린도프릴 및 이의 약학적으로 허용되는 염의 합성 방법 | |
HK1053309B (en) | Method for synthesis of perindopril and its pharmaceutically acceptable salts | |
HK1089187A1 (zh) | 培哚普利及其可药用盐的新合成方法 | |
HK1089187B (en) | Novel method for the synthesis of perindopril and the pharmaceutically acceptable salts thereof | |
HK1089188B (en) | Novel method of synthesising perindopril and the pharmaceutically-acceptable salts thereof | |
HK1095840A1 (en) | Method for the synthesis of derivatives of (2s,3as,7as)-1[(s)-alanyl]-octahydro-1h-indole-2-carboxylic acid and use thereof for the synthesis of perindopril | |
HK1086281A1 (en) | Novel method for synthesising perindopril and the pharmaceutically acceptable salt thereof | |
HK1096407B (en) | Novel method for the synthesis of perindopril and the pharmaceutically acceptable salts thereof | |
HK1095840B (en) | Method for the synthesis of derivatives of (2s,3as,7as)-1[(s)-alanyl]-octahydro-1h-indole-2-carboxylic acid and use thereof for the synthesis of perindopril |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PA0105 | International application |
Patent event date: 20021005 Patent event code: PA01051R01D Comment text: International Patent Application |
|
A201 | Request for examination | ||
PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20021011 Comment text: Request for Examination of Application |
|
PG1501 | Laying open of application | ||
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20041130 Patent event code: PE09021S01D |
|
E701 | Decision to grant or registration of patent right | ||
PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20050629 |
|
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20050802 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20050803 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration | ||
PR1001 | Payment of annual fee |
Payment date: 20080602 Start annual number: 4 End annual number: 4 |
|
PR1001 | Payment of annual fee |
Payment date: 20090608 Start annual number: 5 End annual number: 5 |
|
PR1001 | Payment of annual fee |
Payment date: 20100603 Start annual number: 6 End annual number: 6 |
|
PR1001 | Payment of annual fee |
Payment date: 20110530 Start annual number: 7 End annual number: 7 |
|
PR1001 | Payment of annual fee |
Payment date: 20120724 Start annual number: 8 End annual number: 8 |
|
FPAY | Annual fee payment |
Payment date: 20130610 Year of fee payment: 9 |
|
PR1001 | Payment of annual fee |
Payment date: 20130610 Start annual number: 9 End annual number: 9 |
|
FPAY | Annual fee payment |
Payment date: 20140529 Year of fee payment: 10 |
|
PR1001 | Payment of annual fee |
Payment date: 20140529 Start annual number: 10 End annual number: 10 |
|
FPAY | Annual fee payment |
Payment date: 20150617 Year of fee payment: 11 |
|
PR1001 | Payment of annual fee |
Payment date: 20150617 Start annual number: 11 End annual number: 11 |
|
FPAY | Annual fee payment |
Payment date: 20170614 Year of fee payment: 13 |
|
PR1001 | Payment of annual fee |
Payment date: 20170614 Start annual number: 13 End annual number: 13 |
|
LAPS | Lapse due to unpaid annual fee | ||
PC1903 | Unpaid annual fee |
Termination category: Default of registration fee Termination date: 20190513 |